Reducing Breathlessness With Dronabinol in COPD Patients

Phase 3 Recruiting 30 enrolled Vejle Hospital Odense Patient Data Explorative Network · collab Region of Southern Denmark · collab University of Aarhus · collab University of Southern Denmark · collab

RandomizedCrossoverQuadruple-blindSupportive care

Summary

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).

Timeline

Start: 2025-02-26
Primary completion: 2026-09
Completion: 2026-10

Publications

Wolsing SK, Hilberg O, Lokke A, Farver-Vestergaard I, Andersen CU, Hansen KK. Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark - a study protocol. BMJ Open. 2026 Feb 16;16(2):e104957. doi: 10.1136/bmjopen-2025-104957.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dronabinol	Other / unclassified	20 mg	—

Reducing Breathlessness With Dronabinol in COPD Patients

Summary

Timeline

Publications

Drugs

Indications